The Choice of Treatment Methods and Efficacy of LABC

Local advanced breast cancer was enrolled in the Department of Breast Surgery of Peking Union Medical College Hospital and Beijing Cooperation Hospital according to the criteria for patient inclusion. It is estimated that 50 patients will be enrolled. Randomly divide patients into two groups. The plan for Group A (experimental group, 25 cases) is "surgery+systematic treatment"; The plan for Group B (control group, 25 cases) is "neoadjuvant therapy+surgery+systematic treatment". Based on the previously obtained patient personal information, treatment related information, tumor tissue/blood sample test results, statistical analysis was conducted to explore the impact of different treatment strategies for locally advanced breast cancer on the survival and prognosis of patients.

Inclusion criteria

• 18-70 year old female
• Patients with locally advanced breast cancer (stage IIIb - IIIc) first diagnosed;
• Clinical diagnosis of breast cancer, or puncture pathology suggests breast cancer;
• After evaluation by experienced clinical physicians, the patient's tumor has the possibility of surgical resection. Specific evaluation indicators include ultrasound assessment of the tumor not surrounding the axillary vein;
• Accept treatment plans including surgery, radiotherapy, and chemotherapy;
• Volunteer to participate in clinical research and sign an informed consent form;
• Willing to undergo follow-up and complete quality of life (EQ-5D series scale and FACT-B scale) and postoperative psychological status (Anxiety/Depression Self Rating Scale) assessments;

Exclusion criteria

• Patients under 18 years old or over 70 years old;
• Those who have received breast cancer related surgery, radiotherapy or chemotherapy;
• Those who are not expected to receive surgery, radiotherapy or chemotherapy related to breast cancer
• History of other malignant tumors;
• Pregnant or lactating women;
• Accompanying active infection and fever;
• Other serious diseases that may significantly affect clinical trial compliance, such as severe cardiopulmonary dysfunction, liver and kidney dysfunction, poorly controlled diabetes and mental illness.